Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CBER
Biotech
FDA leadership 'decapitated,' former leader Janet Woodcock says
The restructuring will have a “disproportionate effect” on rare disease drug development, according to former FDA lawyer Frank Sasinowski.
Gabrielle Masson
Apr 7, 2025 4:04pm
CBER deputy director departs amid mass exodus
Feb 21, 2025 5:20pm
Moderna rare disease drug nabs spot in FDA pilot program
Jun 7, 2024 6:10am
FDA picks Denali, Neurogene and more for rare disease program
Jun 4, 2024 2:51pm
FDA's new platform guidance aims to smooth regulatory encounters
May 30, 2024 7:30am
FDA's Peter Marks doesn't plan to retire soon—Chutes & Ladders
Aug 4, 2023 9:30am
